Page last updated: 2024-11-04

myristicin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

myristicin: asaricin is an isomer; structure; a methylene dioxy version of elemicin; [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4276
CHEMBL ID481044
CHEBI ID68234
SCHEMBL ID68041
MeSH IDM0046650

Synonyms (62)

Synonym
5-19-02-00631 (beilstein handbook reference)
04pd6ct78w ,
unii-04pd6ct78w
1,3-benzodioxole, 4-methoxy-6-(2-propenyl)-
benzene, 5-allyl-1-methoxy-2,3-(methylenedioxy)-
einecs 210-146-9
4-methoxy-6-(2-propenyl)-1,3-benzodioxole
brn 0166218
hsdb 3516
ccris 6782
5-allyl-1-methoxy-2,3-(methylenedioxy)benzene
NCGC00091427-01
MLS001065535
smr000112534
myristicin
C10480
607-91-0
6-allyl-4-methoxy-1,3-benzodioxole
4-methoxy-6-[2-propenyl]-1,3-benzodioxole
chebi:68234 ,
CHEMBL481044
4-methoxy-6-prop-2-enyl-1,3-benzodioxole
AKOS005604763
NCGC00091427-02
STK693140
4-methoxy-6-(prop-2-en-1-yl)-1,3-benzodioxole
tox21_200172
dtxsid1025693 ,
NCGC00257726-01
cas-607-91-0
dtxcid605693
HMS2270K14
S3291
FT-0672575
5-allyl-1-methoxy-2,3-methylenedioxybenzene
myristicin [hsdb]
myristicin [mi]
CCG-208543
SCHEMBL68041
AC-34678
myristicine
5-allyl-2,3-(methylendioxy)anisole
mfcd00133549
4-methoxy-6-(prop-2-en-1-yl)-2h-1,3-benzodioxole
sr-01000838340
SR-01000838340-3
myristicin, analytical standard
1-methoxy-2,3-methylenedioxy-5-(2-propenyl)benzene
4-methoxy-6-(2-propenyl)-1,3-benzodioxole, 9ci
1,3-benzodioxole, 4-methoxy-6-(2-propenyl)- (9ci)
1-allyl-3-methoxy-4,5-methylenedioxybenzene
5-allyl-1-methoxy-2,3-(methylenedioxy)-benzene
myristicin (6ci)
myristicin_major
Q414057
CS-0022781
HY-N2510
6-allyl-4-methoxybenzo[d][1,3]dioxole
bdbm50242966
6-allyl-4-methoxy-benzo-1,3-dioxole
MS-23038
6-allyl-1,3-benzodioxol-4-yl methyl ether

Research Excerpts

Overview

Myristicin is a natural active compound that has inflammatory, antimicrobial and anti-proliferative properties.

ExcerptReferenceRelevance
"Myristicin is a type of natural compound showing anti-proliferative, anti-microbial, and anti-inflammatory effects. "( Myristicin Suppresses Gastric Cancer Growth
Bai, Y; Chen, Z; He, S; Li, B; Song, J; Wang, N; Xu, X; Zhang, S, 2023
)
3.8
"Myristicin is a natural active compound that has inflammatory, antimicrobial and anti-proliferative properties. "( Anticancer effect of myristicin on hepatic carcinoma and related molecular mechanism.
Bao, H; Muge, Q, 2021
)
2.38

Effects

Myristicin has a very weak fluorescence and also lacks derivatizable groups like the carboxylic, hydroxyl, or amino group in its structure. It has been known to have anti-cholinergic, antibacterial,and hepatoprotective effects. The effects of myristicins on virus-stimulated macrophages are not fully reported.

ExcerptReferenceRelevance
"Myristicin has a very weak fluorescence and also lacks derivatizable groups like the carboxylic, hydroxyl, or amino group in its structure, which makes its fluorescence derivatization challenging."( Selective fluorescence labeling of myristicin using Mizoroki-Heck coupling reaction. Application to nutmeg powder, oil, and human plasma samples.
El-Maghrabey, MH; Fukuda, T; Iwata, H; Kawakami, S; Kishikawa, N; Kuroda, N; Ohyama, K; Wada, M, 2022
)
1.72
"Myristicin has a very weak fluorescence and also lacks derivatizable groups like the carboxylic, hydroxyl, or amino group in its structure, which makes its fluorescence derivatization challenging."( Selective fluorescence labeling of myristicin using Mizoroki-Heck coupling reaction. Application to nutmeg powder, oil, and human plasma samples.
El-Maghrabey, MH; Fukuda, T; Iwata, H; Kawakami, S; Kishikawa, N; Kuroda, N; Ohyama, K; Wada, M, 2022
)
1.72
"Myristicin has been known to have anti-cholinergic, antibacterial,and hepatoprotective effects, however, the effects of myristicin on virus-stimulated macrophages are not fully reported."( Anti-inflammatory effect of myristicin on RAW 264.7 macrophages stimulated with polyinosinic-polycytidylic acid.
Lee, JY; Park, W, 2011
)
1.38

Treatment

ExcerptReferenceRelevance
"Myristicin treatment caused a slight change in the GST pi levels while the levels of GST alpha showed a modest increase."( Preferential overexpression of a class MU glutathione S-transferase subunit in mouse liver by myristicin.
Ahmad, H; Tijerina, MT; Tobola, AS, 1997
)
1.24

Toxicity

ExcerptReferenceRelevance
", fungi that produce toxic aflatoxins."( Effects of a naturally occurring and a synthetic synergist on toxicity of three insecticides and a phytochemical to navel orangeworm (Lepidoptera: Pyralidae).
Berenbaum, MR; Lawrance, A; Niu, G; Pollock, HS; Siegel, JP, 2012
)
0.38
" This case highlights that nutmeg, a spice, can cause serious toxic effects like status epilepticus."( Myristicin and phenytoin toxicity in an infant.
David, HS; Rajavelu, KK; Sampath, S; Sivathanu, S, 2014
)
1.85
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (25)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency22.68630.003041.611522,387.1992AID1159555
pregnane X nuclear receptorHomo sapiens (human)Potency35.95530.005428.02631,258.9301AID1346982
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency0.63100.001024.504861.6448AID588535
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency70.79460.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency0.58050.004611.374133.4983AID624296
survival motor neuron protein isoform dHomo sapiens (human)Potency31.62280.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency10.00000.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sialidase AStreptococcus pneumoniaeIC50 (µMol)196.90000.30005.050010.0000AID1467530
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (43)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID376048Antifungal activity against Epidermophyton floccosum C 114 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376052Antifungal activity against Aspergillus flavus ATCC 9170 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID1541175Cytotoxicity against mouse RAW264.7 cells assessed as effect on cell viability at 10 uM by CCK-8 assay2019Journal of natural products, 11-22, Volume: 82, Issue:11
Lignans from
AID376054Antifungal activity against Aspergillus niger ATCC 9029 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID1327072Antagonist activity at human EGFP-fused CCR3 expressed in mouse L1.2 cells assessed as inhibition of CCL11-induced chemotaxis at 1 uM measured after 1.5 hrs by PicoGreen dsDNA reagent-based assay2016Journal of natural products, 08-26, Volume: 79, Issue:8
Neolignans from the Arils of Myristica fragrans as Potent Antagonists of CC Chemokine Receptor 3.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID376051Antifungal activity against Cryptococcus neoformans ATCC 32264 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID1467530Inhibition of Streptococcus pneumoniae sialidase NanA using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid as substrate after 60 mins by FRET assay2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Sialidase inhibitory activity of diarylnonanoid and neolignan compounds extracted from the seeds of Myristica fragrans.
AID376046Antifungal activity against Trichophyton mentagrophytes ATCC by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376047Antifungal activity against Trichophyton rubrum C 113 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID376049Antifungal activity against Candida albicans ATCC 10231 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376055Antifungal activity against Microsporum canis C 112 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID1467533Inhibition of Streptococcus pneumoniae sialidase NanC using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid as substrate after 60 mins by FRET assay2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Sialidase inhibitory activity of diarylnonanoid and neolignan compounds extracted from the seeds of Myristica fragrans.
AID376053Antifungal activity against Aspergillus fumigatus ATCC 26934 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID332622Antifungal activity against Cladosporium cucumerinum assessed as inhibition of spore growth by TLC bioassay1995Journal of natural products, Jan, Volume: 58, Issue:1
Isolation of antifungal and larvicidal constituents of Diplolophium buchanani by centrifugal partition chromatography.
AID376043Antifungal activity against Trichophyton rubrum C 113 up to 50 ug/mL by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376044Antifungal activity against Epidermophyton floccosum C 114 up to 50 ug/mL by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID592240Inhibition of yeast alpha-glucosidase assessed as inhibition of p-nitrophenyl-alpha-D-glucopyranoside substrate hydrolysis after 35 mins by spectroscopy2011Journal of natural products, Mar-25, Volume: 74, Issue:3
(Z)-3-butylidenephthalide from Ligusticum porteri , an α-glucosidase inhibitor.
AID376041Antifungal activity against Microsporum gypseum C 115 up to 50 ug/mL by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID1541174Inhibition of LPS-induced NO production in mouse RAW264.7 cells incubated for 24 hrs in presence of LPS by Griess reagent based assay2019Journal of natural products, 11-22, Volume: 82, Issue:11
Lignans from
AID376050Antifungal activity against Saccharomyces cerevisiae ATCC 9763 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376040Antifungal activity against Microsporum canis C 112 up to 50 ug/mL by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID376045Antifungal activity against Microsporum gypseum C 115 by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID550213Antimitotic activity against Paracentrotus lividus embryo assessed as cleavage alteration up to 80 to 100 uM after 2.5 to 6 hrs post fertilization by sea urchin embryo assay2010Journal of natural products, Nov-29, Volume: 73, Issue:11
Synthesis of antimitotic polyalkoxyphenyl derivatives of combretastatin using plant allylpolyalkoxybenzenes.
AID332623Larvicidal activity against Aedes aegypti larvae after 24 hrs by TLC bioassay1995Journal of natural products, Jan, Volume: 58, Issue:1
Isolation of antifungal and larvicidal constituents of Diplolophium buchanani by centrifugal partition chromatography.
AID1467529Inhibition of Streptococcus pneumoniae sialidase NanB using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid as substrate after 60 mins by FRET assay2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Sialidase inhibitory activity of diarylnonanoid and neolignan compounds extracted from the seeds of Myristica fragrans.
AID376042Antifungal activity against Trichophyton mentagrophytes ATCC 9972 up to 50 ug/mL by agar dilution method1999Journal of natural products, Oct, Volume: 62, Issue:10
In vitro evaluation of antifungal properties of phenylpropanoids and related compounds acting against dermatophytes.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (115)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (8.70)18.7374
1990's17 (14.78)18.2507
2000's23 (20.00)29.6817
2010's45 (39.13)24.3611
2020's20 (17.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 55.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index55.64 (24.57)
Research Supply Index4.79 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index91.05 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (55.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (5.04%)6.00%
Case Studies4 (3.36%)4.05%
Observational0 (0.00%)0.25%
Other109 (91.60%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]